Additional Programs

The melanocortin system can be leveraged for much more than optimizing body weight. Beyond obesity and cachexia, Kalohexis’ pipeline includes MC4R-selective and MC3R-selective agonists with the potential to address multiple high-value and underserved metabolic and substance use disorder indications, including type 2 diabetes and metabolic dysfunction-associated steatohepatitis (MASH).